Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $25.4 million.

  • Zenas BioPharma's Non-Current Assets rose 16285.48% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.9 million, marking a year-over-year change of. This contributed to the annual value of $14.0 million for FY2024, which is 6768.15% up from last year.
  • Zenas BioPharma's Non-Current Assets amounted to $25.4 million in Q3 2025, which was up 16285.48% from $14.5 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Non-Current Assets ranged from a high of $25.4 million in Q3 2025 and a low of $8.4 million during Q4 2023
  • For the 3-year period, Zenas BioPharma's Non-Current Assets averaged around $14.6 million, with its median value being $14.3 million (2024).
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 6768.15% in 2024, then surged by 16285.48% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's Non-Current Assets stood at $8.4 million in 2023, then skyrocketed by 67.68% to $14.0 million in 2024, then surged by 80.68% to $25.4 million in 2025.
  • Its last three reported values are $25.4 million in Q3 2025, $14.5 million for Q2 2025, and $16.0 million during Q1 2025.